5 things to know before the stock market opens Thursday

Here are the most important news, trends and analysis that investors need to start their trading…

Patient receives first infusion of Biogen’s controversial Alzheimer’s drug

The exterior of the headquarters of biotechnology company Biogen in Cambridge, MA is pictured on March…

Biogen Alzheimer’s drug and the battle over dementia treatment of the future

Aduhelm by Biogen Source: Biogen The FDA’s approval of Biogen‘s Alzheimer’s drug Aduhelm was a landmark…

Stocks making the biggest moves midday: Chewy, Biogen, Snowflake and more

Signage is seen ahead of the IPO for Chewy at the New York Stock Exchange, June…

Third member of prestigious FDA panel resigns over approval of Biogen’s Alzheimer’s drug

A sign for the Food and Drug Administration is seen outside of the headquarters on July…

Biogen’s new Alzheimer’s drug could cost Medicare billions of dollars a year, report finds

A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam…

Biogen faces tough questions over $56K-a-year price of newly approved Alzheimer’s drug

A person skateboards past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam…

Dementia expert says evidence behind Biogen Alzheimer’s drug ‘wasn’t sufficient’ for FDA approval

Dementia expert Dr. Jason Karlawish told CNBC he’s skeptical of the Food and Drug Administration’s approval…

Biogen CEO says $56,000 annually for Alzheimer’s drug is ‘fair,’ promises not to hike price for at least 4 years

Biogen CEO Michel Vounatsos told CNBC on Monday that the list price of $56,000 per year…

Stocks making the biggest moves midday: Biogen, Eli Lilly and AMC

The exterior of the headquarters of biotechnology company Biogen in Cambridge, MA is pictured on March…

Translate »